Jendoubi Fatma, Rohde Manfred, Prinz Jörg Christoph
Department of Dermatology, University Clinics, Ludwig-Maximilian University of Munich, Munich, Germany.
Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.
Front Med (Lausanne). 2019 Jan 29;6:6. doi: 10.3389/fmed.2019.00006. eCollection 2019.
Erysipelas is a severe streptococcal infection of the skin primarily spreading through the lymphatic vessels. Penicillin is the treatment of choice. The most common complication consists in relapses which occur in up to 40% or more of patients despite appropriate antibiotic treatment. They cause lymphatic damage resulting in irreversible lymphedema and ultimately elephantiasis nostras and lead to major health restrictions and high socio-medical costs. Prevention of relapses is an unmet need, because even long-term prophylactic penicillin application does eventually not reduce the risk of recurrence. In this article we assess risk factors and causes of erysipelas recurrence. A systematic literature search for clinical studies addressing potential causes and measures for prevention of erysipelas recurrence was combined with a review of experimental and clinical data assessing the ability and clinical relevance of streptococci for intracellular uptake and persistence. The literature review found that venous insufficiency, lymphedema, and intertrigo from fungal infections are considered to be major risk factors for recurrence of erysipelas but cannot adequately explain the high recurrence rate. As hitherto unrecognized likely cause of erysipelas relapses we identify the ability of streptococci for intracellular uptake into and persistence within epithelial and endothelial cells and macrophages. This creates intracellular streptococcal reservoirs out of reach of penicillins which do not reach sufficient bactericidal intracellular concentrations. Incomplete streptococcal elimination due to intracellular streptococcal persistence has been observed in various deep tissue infections and is considered as cause of relapsing streptococcal pharyngitis despite proper antibiotic treatment. It may also serves as endogenous infectious source of erysipelas relapses. We conclude that the current antibiotic treatment strategies and elimination of conventional risk factors employed in erysipelas management are insufficient to prevent erysipelas recurrence. The reactivation of streptococcal infection from intracellular reservoirs represents a plausible explanation for the frequent occurrence erysipelas relapses. Prevention of erysipelas relapses therefore demands for novel antibiotic strategies capable of eradicating intracellular streptococcal persistence.
丹毒是一种主要通过淋巴管传播的严重皮肤链球菌感染。青霉素是首选治疗药物。最常见的并发症是复发,尽管进行了适当的抗生素治疗,但高达40%或更多的患者会出现复发。复发会导致淋巴损伤,进而导致不可逆的淋巴水肿,最终发展为象皮肿,并导致严重的健康限制和高昂的社会医疗成本。预防复发是一个尚未满足的需求,因为即使长期应用预防性青霉素最终也不能降低复发风险。在本文中,我们评估了丹毒复发的危险因素和原因。对涉及丹毒复发潜在原因和预防措施的临床研究进行系统的文献检索,并结合对评估链球菌细胞内摄取能力和持续性的实验及临床数据的综述。文献综述发现,静脉功能不全、淋巴水肿和真菌感染引起的擦烂被认为是丹毒复发的主要危险因素,但无法充分解释高复发率。作为迄今未被认识的丹毒复发可能原因,我们确定了链球菌进入上皮细胞、内皮细胞和巨噬细胞并在其中持续存在的细胞内摄取能力。这会形成青霉素无法触及的细胞内链球菌储存库,因为青霉素无法在细胞内达到足够的杀菌浓度。在各种深部组织感染中都观察到由于细胞内链球菌持续存在导致的链球菌清除不完全,这被认为是尽管进行了适当的抗生素治疗但仍发生复发性链球菌咽炎的原因。它也可能是丹毒复发的内源性感染源。我们得出结论,目前丹毒管理中采用的抗生素治疗策略和消除传统危险因素不足以预防丹毒复发。细胞内储存库中链球菌感染的重新激活是丹毒频繁复发的一个合理的解释。因此,预防丹毒复发需要能够根除细胞内链球菌持续存在的新型抗生素策略。